Annual Information Update

RNS Number : 3831B

Hikma Pharmaceuticals Plc

16 April 2012

 



Annual Information Update

London, 16 April 2012.  In accordance with Prospectus Rule 5.2, Hikma Pharmaceuticals PLC ("Hikma" or "the Company") (LSE: HIK) sets out below a summary of the information which has been published or made available to the public over the period. The information referred to in this Update was up to date at the time the information was published, but some information may now be out of date.

Stock Exchange Announcements

Announcements made by the Company via RNS, a Regulatory Information Service, may be viewed and downloaded from the Company's market news section on the London Stock Exchange website at (http://www.londonstockexchange.com/prices-and-news/stocks/stocks-and-prices.htm) or from the press releases page on the Company's website at (http://www.hikma.com/investorrelations/rns/). The Stock Exchange announcements made during the period were:

Date of Announcement	Headline of Announcement
13/04/2012	Annual Financial Report & AGM Notice
04/04/2012	Company Secretary Change
02/04/2012	Total Voting Rights
02/04/2012	Blocklisting Interim Review
28/03/2012	Director/PDMR Shareholding
19/03/2012	Director/PDMR Shareholding
16/03/2012	Director/PDMR Shareholding
14/03/2012	Preliminary Results
12/03/2012	Holding(s) in Company
14/02/2012	Total Voting Rights
02/02/2012	Holding(s) in Company
01/02/2012	Director Declaration
17/01/2012	Tender Offer
13/01/2012	Director/PDMR Shareholding
12/01/2012	Total Voting Rights
22/12/2011	Additional Listing
02/12/2011	Tender Offer
01/12/2011	Holding(s) in Company
11/11/2011	Total Voting Rights
04/11/2011	Interim Management Statement
24/10/2011	Director/PDMR Shareholding
18/10/2011	Director/PDMR Shareholding
18/10/2011	Director/PDMR Shareholding
18/10/2011	Director/PDMR Shareholding
17/10/2011	Tender Offer
07/10/2011	Blocklisting Interim Review
06/10/2011	Dividend Declaration
03/10/2011	Acquisition
25/08/2011	Directorate Change
25/08/2011	Interim Results
19/08/2011	Trading Statement
26/07/2011	Total Voting Rights
11/07/2011	Hikma enhances its API sourcing capabilities
01/06/2011	Total Voting Rights
26/05/2011	Director/PDMR Shareholding
25/05/2011	Holding(s) in Company
17/05/2011	Director/PDMR Shareholding
13/05/2011	Director/PDMR Shareholding
13/05/2011	Dividend Declaration
12/05/2011	AGM Statement
12/05/2011	Interim Management Statement
09/05/2011	Director/PDMR Shareholding
09/05/2011	Total Voting Rights
09/05/2011	Annual Information Update
03/05/2011	Statement re Completion of Acquisition

All of the above announcements were also made by the Company via the Nasdaq Dubai stock exchange CANDI system.  These announcements may be viewed and downloaded from the Nasdaq Dubai website (www.candi.nasdaq.com). 

Documents filed with the Financial Services Authority

The Company has filed the following documents with the Financial Services Authority ("FSA") visa the National Storage Mechanism over the previous 12 months.  These documents are available at http://www.hemscott.com/nsm.do or at the Company's registered office.

Date	Document
13 April 2012	Annual Report and Accounts 2011
13 April 2012	Notice of 2012 Annual General Meeting
13 April 2012	Proxy forms for the 2012 Annual General Meeting

Documents filed with Companies House

The Company submitted filings to the Registrar of Companies in England and Wales as detailed in the table below. 

Date Filed	Form	Description
11/04/2012	AP03	Secretary Appointed, Peter Alexander Speirs
11/04/2012	TM02	Secretary Appointment Terminated, Henry Knowles
22/03/2012	SH01	31/01/12 Statement of Capital GBP 19,586,621
22/03/2012	SH01	22/03/12 Statement of Capital GBP 19,586,621
12/01/2012	SH01	31/12/11 Statement of Capital GBP 19,582,971
28/11/2011	SH01	31/10/11 Statement of Capital GBP 19,535,931
21/10/2011	MG01	Particulars of a Mortgage or Charge / Charge No: 1
19/09/2011	RES01	Adopt Articles 13/05/2010
19/09/2011	CC04	Statement of Company's Objects
12/09/2011	AR01	08/09/11 Full List
02/09/2011	AP01	Director Appointed Robert Mark Pickering
18/08/2011	SH01	30/06/11 Statement of Capital GBP 19,533,781
29/06/2011	SH01	31/05/11 Statement of Capital GBP 19,491,421
20/05/2011	RES13	Approval of Waiver 12/05/2011
19/05/2011	AA	Group of Companies' Accounts Made up to 31/12/10
10/05/2011	SH01	30/04/11 Statement of Capital GBP 19,485,361

Copies of all these documents may be obtained from Companies House, Crown Way, Maindy, Cardiff CF14 3UZ or, if you are a registered user, they may be viewed and downloaded using Companies House Direct at www.direct.companieshouse.gov.uk.

Further Information

Further information about Hikma Pharmaceuticals PLC can be found at our website www.hikma.com. Copies of all documents can be obtained from the Company at the registered office which is located at 13 Hanover Square, London W1S 1HW.

Peter Speirs

Company Secretary
16 April 2012

- ENDS -

Enquiries:

Hikma Pharmaceuticals PLC
Peter Speirs Company Secretary	[phone]

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non‐branded generic and in‐licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2011, Hikma achieved revenue of $918.0 million and profit attributable to shareholders of $80.1 million.

 

END

 

 

AIUVQLBFLZFEBBQ